It's great to have a favourable spotlight on axovant's new play as a gt company. Esp when potential investors look at the companies involved in their gene therapy pipeline..
Axovant's gene therapy pipeline
Project
Indication
Originator
Cost
AXO-Lenti-PD
Parkinson's disease
Oxford Biomedica
$30m up front
AXO-AAV-GM2
Tay-Sachs & Sandhoff diseases
University of Massachusetts Medical School
Undisclosed
AXO-AAV-GM1
GM1 gangliosidosis
University of Massachusetts Medical School
AXO-AAV-OPMD
Oculopharyngeal muscular dystrophy
Benitec
$10m up front
AXO-AAV-ALS
Amyotrophic lateral sclerosis
Benitec
AXO-AAV-FTD
Frontotemporal dementia
Benitec
BLT Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held